Подкатегории
pharmachologic effect
Antipsychotic (antipsychotic). The therapeutic effect of aripiprazole in schizophrenia is believed to be due to a combination of partial agonistic activity against dopamine D2 and serotonin 5-HT1 receptors and antagonistic activity against serotonin 5-HT2 receptors.
on prescription
Manufacturer BRISTOL-MYERS
pharmachologic effect
Antipsychotic (antipsychotic). The therapeutic effect of aripiprazole in schizophrenia is believed to be due to a combination of partial agonistic activity against dopamine D2 and serotonin 5-HT1 receptors and antagonistic activity against serotonin 5-HT2 receptors.
on prescription
Manufacturer BRISTOL-MYERS
pharmachologic effect
Antipsychotic (antipsychotic). The therapeutic effect of aripiprazole in schizophrenia is believed to be due to a combination of partial agonistic activity against dopamine D2 and serotonin 5-HT1 receptors and antagonistic activity against serotonin 5-HT2 receptors.
on prescription
Manufacturer BRISTOL-MYERS
pharmachologic effect
Antipsychotic (antipsychotic). The therapeutic effect of aripiprazole in schizophrenia is believed to be due to a combination of partial agonistic activity against dopamine D2 and serotonin 5-HT1 receptors and antagonistic activity against serotonin 5-HT2 receptors.
on prescription
Manufacturer BRISTOL-MYERS
From the nervous system and sensory organs: increased fatigue, weakness, dizziness, drowsiness, anxiety, confusion, euphoria, impaired memory, hallucinations, mydriasis, disturbance of accommodation.
prescription
Manufacturer BAYER
pharmachologic effect
Antipsychotic (antipsychotic). The therapeutic effect of aripiprazole in schizophrenia is believed to be due to a combination of partial agonistic activity against dopamine D2 and serotonin 5-HT1 receptors and antagonistic activity against serotonin 5-HT2 receptors.
on prescription
Manufacturer BRISTOL-MYERS
pharmachologic effect
Antipsychotic (antipsychotic). The therapeutic effect of aripiprazole in schizophrenia is believed to be due to a combination of partial agonistic activity against dopamine D2 and serotonin 5-HT1 receptors and antagonistic activity against serotonin 5-HT2 receptors.
on prescription
Manufacturer BRISTOL-MYERS
pharmachologic effect
Antipsychotic (antipsychotic). The therapeutic effect of aripiprazole in schizophrenia is believed to be due to a combination of partial agonistic activity against dopamine D2 and serotonin 5-HT1 receptors and antagonistic activity against serotonin 5-HT2 receptors.
on prescription
Manufacturer BRISTOL-MYERS
Dementia in Alzheimer's disease (mild to moderate) in adults, including the elderly (symptomatic treatment). Symptomatic treatment of mild to moderate Alzheimer's dementia.
Dementia in Alzheimer's disease (mild to moderate) in adults, including the elderly (symptomatic treatment). Symptomatic treatment of mild to moderate Alzheimer's dementia.
Dementia in Alzheimer's disease (mild to moderate) in adults, including the elderly (symptomatic treatment). Symptomatic treatment of mild to moderate Alzheimer's dementia.
Application of Encephabol. The drug is a means of affecting brain damage (nootropic). Areas of application Symptomatic treatment of chronic brain organic disorders in dementia with the following main symptoms: memory impairment, impaired concentration, thinking disorders, premature fatigue, lack of motivation and motivation, affective disorders.
Application of Encephabol. The drug is a means of affecting brain damage (nootropic). Areas of application Symptomatic treatment of chronic brain organic disorders in dementia with the following main symptoms: memory impairment, impaired concentration, thinking disorders, premature fatigue, lack of motivation and motivation, affective disorders.
Application of Encephabol. The drug is a means of affecting brain damage (nootropic). Areas of application Symptomatic treatment of chronic brain organic disorders in dementia with the following main symptoms: memory impairment, impaired concentration, thinking disorders, premature fatigue, lack of motivation and motivation, affective disorders.
Application of Encephabol. The drug is a means of affecting brain damage (nootropic). Areas of application Symptomatic treatment of chronic brain organic disorders in dementia with the following main symptoms: memory impairment, impaired concentration, thinking disorders, premature fatigue, lack of motivation and motivation, affective disorders.